Synonyms: Cataclot® | KCT-0809 | OKY-046 | Pulmoza®
ozagrel is an approved drug (China and Japan only)
Compound class:
Synthetic organic
Comment: Ozagrel is a thromboxane A synthetase (CYP5A1; TBXAS1) inhibitor that has anti-inflammatory action [3]. Note that some of the bioactivity data for ozagrel relate to use of ozagrel sodium or ozagrel hydrochloride.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Hibi S, Okamoto Y, Tagami K, Numata H, Kobayashi N, Shinoda M, Kawahara T, Harada K, Miyamoto K, Yamatsu I. (1996)
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem, 39 (16): 3148-57. [PMID:8759636] |
2. Hiraku S, Taniguchi K, Wakitani K, Omawari N, Kira H, Miyamoto T, Okegawa T, Kawasaki A, Ujiie A. (1986)
Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046). Jpn J Pharmacol, 41 (3): 393-401. [PMID:3093741] |
3. Yamaguchi M, Kamei K, Koga T, Akima M, Maruyama A, Kuroki T, Ohi N. (1993)
Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones. J Med Chem, 36 (25): 4061-8. [PMID:8258828] |